Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
BioNTech SE, headquartered in Mainz, Germany, is a leading player in the Research and Development sector of biotechnology, excluding nanobiotechnology. Founded in 2008, the company has made significant strides in mRNA technology, particularly in the development of innovative therapies and vaccines for infectious diseases and cancer.
With a strong focus on personalised medicine, BioNTech's core products include its groundbreaking mRNA-based vaccines, which gained global recognition during the COVID-19 pandemic. The company has established itself as a pioneer in the biotechnology field, achieving notable milestones such as the rapid development of its COVID-19 vaccine in collaboration with Pfizer.
BioNTech's commitment to advancing healthcare solutions positions it as a formidable entity in the biotechnology landscape, with a robust pipeline of therapeutic candidates aimed at addressing unmet medical needs.
+17 vs industry average
Biontech’s score of 44 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research and Development in Biotechnology (except Nanobiotechnology) has below-average carbon intensity
The Research and Development in Biotechnology (except Nanobiotechnology) industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
BioNTech, a German biotechnology company, reported total carbon emissions of approximately 711.6 million kg CO2e in 2025. This includes Scope 1 emissions of about 2.2 million kg CO2e, Scope 2 emissions of 0 kg CO2e, and Scope 3 emissions of approximately 703.6 million kg CO2e. This marks a decrease from 2024, where total emissions were about 892.9 million kg CO2e.
BioNTech has committed to several climate targets. They aim to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using a 2021 base year. Additionally, BioNTech commits that 72% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027. These near-term targets are classified as consistent with reductions required to keep warming to 1.5°C by the Science Based Targets initiative (SBTi).
2030
42% reduction in Scope 2
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year.
2030
42% reduction in Scope 1
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Biontech’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more